当前位置： SCI文献检索 > LEUKEMIA & LYMPHOMA期刊下所有文献 > Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.

Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.

Abstract：

:The prognostic significance of rare BCR-ABL1 transcripts is uncertain in the tyrosine kinase inhibitor (TKI) era. In this retrospective study, 40 (1.7%) patients with rare BCR-ABL1 transcripts were identified from a cohort of 2331 chronic myeloid leukemia (CML) patients; 4 types of rare transcripts were identified, including e1a2 (0.9%), e19a2 (0.4%), e13a3 (0.1%), and e14a3 (0.3%). Compared to patients with the typical transcript, those with the e1a2 transcript had an inferior response to TKIs and a worse outcome. Patients with the e19a2 transcript had a high rate of early optimal response to TKIs, but most of them later lost the complete cytogenetic response (CCyR) due to BCR-ABL1 mutations, resulting in a poor prognosis. Patients with the e13a3/e14a3 transcript responded well to TKIs and had a good outcome. These findings indicate that the type of BCR-ABL1 transcript should be considered when determining the treatment for CML patients in the TKI era.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Xue M,Wang Q,Huo L,Wen L,Yang X,Wu Q,Pan J,Cen J,Ruan C,Wu D,Chen S

doi

10.1080/10428194.2019.1607329

subject

Has Abstract

pub_date

2019-12-01 00:00:00

pages

3051-3057

issue

12

eissn

1042-8194

issn

1029-2403

journal_volume

60

pub_type

杂志文章

相关文献

LEUKEMIA & LYMPHOMA文献大全
  • Gastrointestinal Non-Hodgkin's Lymphoma.

    abstract：:The records of 77 patients with gastrointestinal Non-Hodgkin's Lymphoma (GI-NHL) diagnosed from 1972 to 1988 were reviewed. There were 47 male and 30 female patients, median age 56 years (range 20-82 years). Twenty-four patients had stage I disease at presentation, 25 stage II, 8 stage III and 20 stage IV. The primary...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428199109068062

    authors： Stewart AK,Shepherd FA,Goss PE,Warner E,Bailey DJ,Baker MA

    更新日期：1991-01-01 00:00:00

  • Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.

    abstract：:Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent d...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428190600565057

    authors： Faber E,Nausová J,Jarosová M,Egorin MJ,Holzerová M,Rozmanová S,Maresová I,Divoký V,Indrák K

    更新日期：2006-06-01 00:00:00

  • Drug development for recurrent and refractory classical Hodgkin lymphoma.

    abstract：:Classical Hodgkin lymphoma (cHL) is highly treatable with chemotherapy alone or combined modality therapy. High dose therapy and autologous stem cell transplant is considered standard of care for patients who relapse. For patients who relapse following transplant or who are not candidates for high dose therapy, progno...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,评审

    doi：10.1080/10428190902756586

    authors： Wildes TM,Bartlett NL

    更新日期：2009-04-01 00:00:00

  • Comparison of the effects of AcSDKP, thymosin beta4, macrophage inflammatory protein 1alpha and transforming growth factor beta on human leukemic cells.

    abstract：:We have compared the effects of AcSDKP, Thymosin beta4 (Tbeta4), MIP1alpha and TGFbeta on acute myeloid leukemia (AML) and B-lineage acute lymphoid leukemia (B-ALL) cells using liquid cultures in the presence of GM-CSF, IL-3 and SCF for AML cells and IL-3 and IL-7 for ALL cells. Each molecule was added daily and cell ...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428199709058315

    authors： Defard M,Lemoine FM,Bonnet ML,Baillou C,Isnard F,Najman A,Guigon M

    更新日期：1997-11-01 00:00:00

  • Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients.

    abstract：:The lung is a relatively rare site for mucosa-associated lymphoid tissue (MALT) lymphomas: we report the largest available single-center series of patients with this presentation. From August 1992 to October 2000, 12 patients with untreated primary low-grade MALT lymphoma of the lung were submitted either to chemother...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/1042819031000067972

    authors： Zinzani PL,Tani M,Gabriele A,Poletti V,Stefoni V,Alinari L,Musuraca G,Bonifazi F,Pileri S,Tura S,Baccarani M

    更新日期：2003-05-01 00:00:00

  • Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.

    abstract：:Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing ...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428194.2016.1205741

    authors： Pozzi S,Gentile M,Sacchi S,Marcheselli R,Corso A,Cocito F,Musto P,Guarini A,Minoia C,Vincelli I,Ria R,Rivolti E,Mele G,Bari A,Mazzone C,Badiali S,Marcheselli L,Palumbo A,Morabito F

    更新日期：2017-03-01 00:00:00

  • CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.

    abstract：:Few reports on the successful treatment of T-cell large granular lymphocyte (LGL) leukemia with the humanized anti-CD52 monoclonal antibody alemtuzumab are emerging in the literature. The expression of CD52 by LGLs has not been previously investigated. Using semi-quantitative 2- and 3-color flow cytometry, we document...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428190500052156

    authors： Osuji N,Del Giudice I,Matutes E,Morilla A,Owusu-Ankomah K,Morilla R,Dunlop A,Catovksy D

    更新日期：2005-05-01 00:00:00

  • Newer approaches in treating chronic myelogenous leukemia.

    abstract：:We evaluated the recovery of human hematopoietic progenitors in long-term bone marrow culture (LTBMC) initiated in tissue culture (TC) flasks to that in "Lifecell" bags, which are gas-permeable plastic bags in which feeder-layer cells cannot adhere. Cells were incubated in presence of IL-1 and IL-3. Our experiments re...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428199309047901

    authors： Gulati SC,Lemoli R,Van Poznak C

    更新日期：1993-01-01 00:00:00

  • Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.

    abstract：:An increasing incidence of Pneumocystis jiroveci pneumonia (PCP) in patients with B-cell non-Hodgkin lymphoma (B-NHL) receiving rituximab treatment has been reported. We reviewed patients with B-NHL who underwent chemotherapy from 2004 to 2008 at our institution to identify risk factors for PCP development during and ...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428194.2010.506569

    authors： Hashimoto K,Kobayashi Y,Asakura Y,Mori M,Azuma T,Maruyama D,Kim SW,Watanabe T,Tobinai K

    更新日期：2010-10-01 00:00:00

  • Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

    abstract：:Anthracycline uptake could be affected by efflux pumps of the ABC family. The influence of 7 SNPs of ABC genes was evaluated in 225 adult de novo acute myeloid leukemia (AML) patients. After multivariate logistic regression there were no significant differences in complete remission, though induction death was associa...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428194.2016.1231405

    authors： Megías-Vericat JE,Montesinos P,Herrero MJ,Moscardó F,Bosó V,Rojas L,Martínez-Cuadrón D,Hervás D,Boluda B,García-Robles A,Rodríguez-Veiga R,Martín-Cerezuela M,Cervera J,Sendra L,Sanz J,Miguel A,Lorenzo I,Poveda JL,Sanz

    更新日期：2017-05-01 00:00:00

  • Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas.

    abstract：:A heterogeneous group of malignancies are associated with Epstein-Barr virus (EBV) infection. These malignancies arise in both immunosuppressed and immunocompetent individuals and can be divided into three patterns of latency depending on the viral genes that are expressed. In Type III latency malignancies, such as po...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,评审

    doi：10.1080/10428190802311417

    authors： Cohen JI,Bollard CM,Khanna R,Pittaluga S

    更新日期：2008-01-01 00:00:00

  • Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

    abstract：:New therapies for relapsing/refractory Hodgkin lymphoma (R/R HL) and R/R systemic anaplastic large-cell lymphoma (sALCL) have emerged. This study captured utility values for R/R HL and sALCL to support economic evaluation. Health state "vignettes" were developed describing states associated with R/R HL and sALCL: trea...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428194.2014.970542

    authors： Swinburn P,Shingler S,Acaster S,Lloyd A,Bonthapally V

    更新日期：2015-06-01 00:00:00

  • The Wilms tumour gene WT1 in leukaemia.

    abstract：:The WT1 gene is essential for kidney development and is mutated in some Wilms tumours. It is also expressed at a high level in many acute leukaemias and in some haematopoietic progenitor cells, and mutations have been found in leukaemias. The function of WT1, which is a zinc finger protein and has domains characterist...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,评审

    doi：10.3109/10428199709059677

    authors： Pritchard-Jones K,King-Underwood L

    更新日期：1997-10-01 00:00:00

  • Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience.

    abstract：:Little is known about disparities in myelodysplastic syndromes (MDS). We performed a retrospective chart review of patients with MDS (n = 252) evaluated at the University of Maryland Greenebaum Cancer Center between 2000 and 2010. The median age at diagnosis was 65 years, which was lower than the median age of 76 year...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428194.2012.710904

    authors： Zandberg DP,Hendrick F,Vannorsdall E,Bierenbaum J,Tidwell ML,Ning Y,Zhao XF,Davidoff AJ,Baer MR

    更新日期：2013-02-01 00:00:00

  • Peripheral blood lymphocyte subsets of newly diagnosed DLBCL patients and their dynamic changes with rituximab based immunochemotherapy.

    abstract：:The purpose of this study was to explore lymphocyte subsets of newly diagnosed DLBCL patients, and dynamics along with treatment of R-CHOP. A total of 40 DLBCL patients were enrolled. ALC of grade III-IV DLBCL patients was significantly lower than that of health controls (1.33*10E9/L vs 1.89*10E9/L, p = 0.003), mostly...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428194.2019.1617861

    authors： Yang Z,Yu W,Wang S,Zhou X,Liu S,Ma S

    更新日期：2019-12-01 00:00:00

  • Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized

    abstract：:This post-hoc subanalysis of the LYM-3002 phase 3 study assessed the efficacy and safety of substituting vincristine in rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHOP; n = 42) for bortezomib (VR-CAP; n = 38) in a subgroup of 80 mantle cell lymphoma (MCL) patients aged <60 years who did not receive ste...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,随机对照试验

    doi：10.1080/10428194.2017.1365855

    authors： Drach J,Huang H,Samoilova O,Belch A,Farber C,Bosly A,Novak J,Zaucha J,Dascalescu A,Bunworasate U,Masliak Z,Vilchevskaya K,Robak T,Pei L,Rooney B,van de Velde H,Cavalli F

    更新日期：2018-04-01 00:00:00

  • Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability.

    abstract：:The impact of health insurance with inequitable rituximab coverage on the survival of patients with diffuse large B-cell lymphoma (DLBCL) has never been reported. We conducted a nationwide multicenter analysis on the outcome of 553 adult patients consecutively diagnosed with DLBCL between July 2003 and June 2006, in w...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,多中心研究

    doi：10.3109/10428194.2012.698739

    authors： Intragumtornchai T,Bunworasate U,Siritanaratkul N,Khuhapinant A,Nawarawong W,Norasetthada L,Lekhakula A,Rujirojindakul P,Sirijerachai C,Chansung K,Suwanban T,Chuncharunee S,Niparuck P,Wongkhantee S,Mongkonsritragoon W,Numbe

    更新日期：2013-01-01 00:00:00

  • Biological response modifiers render tumor cells susceptible to autologous effector mechanisms by influencing adhesion receptors.

    abstract：:Adhesion molecules such as CD2 and its ligand CD58 (LFA-3), as well as CD11a/18 (LFA-1) and CD54 (ICAM-1) regulate not only cell to cell attachment but also participate in lymphocyte activation, recirculation, and effector function including cytolytic activity towards tumor cells. We have investigated the role of CD2/...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428199309147353

    authors： Schirren CA,Völpel H,Hoffmann JC,Henning SW,Qiao L,Autschbach F,Dengler TJ,Döhner H,Meuer SC

    更新日期：1993-05-01 00:00:00

  • The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.

    abstract：:There are limited data regarding the role of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET-CT) scanning in primary mediastinal B-cell lymphoma (PMBL). We analyzed 28 patients with PMBL treated with chemotherapy, of whom 25 (89%) also received rituximab and 17 (61%) radiotherap...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428194.2014.910656

    authors： Cheah CY,Hofman MS,Seymour JF,Ritchie DS,Dickinson M,Wirth A,Prince HM,Wolf M,Januszcewicz EH,Carney DA,Herbert KE,Harrison SJ,Burbury KL,Tam CS

    更新日期：2015-01-01 00:00:00

  • Tumour kinetics in multiple myeloma before, during, and after treatment.

    abstract：:Tumour progression was monitored in seven multiple myeloma (MM) patients undergoing a novel oral chemotherapy regimen (cyclophosphamide, idarubicin and dexamethasone; CID) followed by early autologous stem cell transplantation (ASCT). Allele-specific oligonucleotide PCR (ASO-PCR) was used to semi-quantitate the number...

    journal_title：Leukemia & lymphoma

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.3109/10428190109057937

    authors： Lincz LF,Crooks RL,Way SL,Granter N,Spencer A

    更新日期：2001-01-01 00:00:00

  • Detection of mutations in GATA1 gene using automated denaturing high-performance liquid chromatography and direct sequencing in children with Down syndrome.

    abstract：:Denaturing high-performance liquid chromatography (dHPLC) was developed to screen DNA variations by separating heteroduplex and homoduplex DNA fragments by ion-pair reverse-phase liquid chromatography. In this study, we have evaluated the dHPLC screening method and direct sequencing for the detection of GATA1 mutation...

    journal_title：Leukemia & lymphoma

    pub_type： 信件

    doi：10.1080/10428190902829433

    authors： Amorim MR,Figueiredo AB,Splendore A,Magalhães IQ,Pombo-de-Oliveira MS,El-Jaick KB,D'andrea ML,Aquino J,Alencar DM,Brandalise SR,Burlemaqui L,Cardoso TC,Carvalho EG,Coser VM,Costa I,Dorea D,Drumond M,Lopes VG,Mendonça

    更新日期：2009-05-01 00:00:00

  • What is the best treatment for acute promyelocytic leukemia?

    abstract：:The modern treatment of acute myelogenous leukemia (AML), consists of a polychemotherapeutic induction treatment followed by a post-remission therapy of variable intensity and duration and acute promyelocytic leukemia (APL) does not differ from this behavior. However, differently from the other AML subtypes, APL shows...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,评审

    doi：10.3109/10428199309064259

    authors： Avvisati G,Petti MC,Mandelli F

    更新日期：1993-01-01 00:00:00

  • Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.

    abstract：:We retrospectively analyzed immunosuppression status in 287 newly diagnosed multiple myeloma (MM) patients and assessed the prognostic value of immunoparesis on survival. Deep immunoparesis was defined that one of uninvolved immunoglobulins was below 50% the lower limit of normal ranges, partial immunoparesis was defi...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428194.2020.1855345

    authors： Geng C,Yang G,Wang H,Wu Y,Leng Y,Zhou H,Zhang Z,Jian Y,Chen W

    更新日期：2020-12-04 00:00:00

  • Analysis of HTLV-I in Hodgkin's Disease.

    abstract：:Both Epstein-Barr virus (EBV) and the human T-cell leukemia virus I (HTLV-I) have been implicated in the generation of human lymphoproliferative disorders such as Burkitt's lymphoma, Hodgkin's disease (HD) and acute T-cell leukemia (ATL). In Hodgkin's disease EBV has been recently detected in Hodgkin's and Sternberg-R...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428199109068088

    authors： Tesch H,Jücker M,Krönke M,Diehl V

    更新日期：1991-01-01 00:00:00

  • The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells.

    abstract：:In this study, we report that the related adhesion focal tyrosine kinase RAFTK, is an upstream kinase in beta1 integrin mediated activation of Akt. Stimulation through beta1 integrins by fibronectin reversed apoptosis induced by adriamycin. Inhibitors of phosphatidylinositol 3-kinase (PI3 kinase)/Akt (LY 294002), tyro...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/1042819021000003009

    authors： Sarkar S,Svoboda M,de Beaumont R,Freedman AS

    更新日期：2002-08-01 00:00:00

  • Selinexor for advanced hematologic malignancies.

    abstract：:Recent measures to classify novel molecular targets with therapeutic potential across multiple hematologic tumors have identified the eukaryotic nuclear exporter, exportin 1 (XPO1), as a promising candidate. Molecular agents termed 'Selective Inhibitors of Nuclear Export' (SINEs) have been developed to selectively inh...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428194.2020.1775210

    authors： Walker JS,Garzon R,Lapalombella R

    更新日期：2020-10-01 00:00:00

  • An unusual case of composite lymphoma involving chronic lymphocytic leukemia follicular lymphoma and Hodgkin disease.

    abstract：:Composite lymphomas constitute the presence of two different types of non-Hodgkin lymphoma or Hodgkin and non-Hodgkin lymphoma at the same anatomic site. We report an unusual case of a 73-year-old woman who initially presented with a composite lymphoma of chronic lymphocytic leukemia (CLL) and follicular lymphoma. Aft...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/1042819032000159870

    authors： Copur MS,Ledakis P,Novinski D,Fu K,Hutchins M,Frankforter S,Mleczko K,Sanger WG,Chan WC

    更新日期：2004-05-01 00:00:00

  • CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.

    abstract：:Platelet/endothelial cell adhesion molecule 1 (PECAM-1, CD31) is an immunoglobulin superfamily member expressed on the surface of platelets, leukocytes and endothelial cells. The role of CD31 in biology of lymphomas has not yet been systemically studied. Expression of cell surface CD31 was analyzed by flow cytometry o...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.1080/10428194.2020.1849678

    authors： Vockova P,Molinsky J,Klanova M,Karban J,Spacek M,Havranek O,Kupcova K,Kazantsev D,Trneny M,Klener P

    更新日期：2020-11-25 00:00:00

  • Cigarette smoking is associated with a small increase in the incidence of non-Hodgkin lymphoma: a meta-analysis of 24 observational studies.

    abstract：:Previous studies have evaluated the association between cigarette smoking and incidence of non-Hodgkin lymphoma (NHL) with inconclusive results. Our main objective was to evaluate this relationship using a meta-analysis of observational studies. A literature search was undertaken through October 2011 looking for perti...

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章,meta分析

    doi：10.3109/10428194.2012.673225

    authors： Castillo JJ,Dalia S

    更新日期：2012-10-01 00:00:00

  • Up-regulation of tissue inhibitor of metalloproteinase-2 promotes SHI-1 cell invasion in nude mice.

    abstract：:The role of tissue inhibitor of metalloproteinase-2 (TIMP-2) in extramedullary infiltration of acute leukemia is unclear. We demonstrated in our previous study that the up-regulation of TIMP-2 promoted SHI-1 cell invasion in vitro. We investigated in the present study whether TIMP-2 would have the same effect in vivo....

    journal_title：Leukemia & lymphoma

    pub_type： 杂志文章

    doi：10.3109/10428194.2013.783214

    authors： Wang C,Cai X,Chen B,He Z,Chen Z,Cen J,Li Z

    更新日期：2013-12-01 00:00:00